@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms (@neurIST)

January 14, 2026 updated by: Philippe Bijlenga, University Hospital, Geneva

@neurIST : Informatique biomédicale intégrée Pour la Gestion Des anévrismes cérébraux

The primary aim of the SwissNeuroFoundation AneurysmDataBase Project is to implement information technology based tools to create and use a holistic reference database specific to intracranial aneurysms (IA).

The SwissNeuroFoundation AneurysmDataBase are concerned with generating the data with which to populate this database.

The purpose for populating the database are to:

  • Screen for and evaluate markers of risk for intracranial aneurysm formation and aneurysm rupture. Are considered as markers the following: genetics factors, microbiota, environmental factors, congenital factors (ie: cerebrovascular anatomical variants), transcriptomics signature, proteomics signature,shape characteristics, haemodynamics characteristics.
  • Screen for and evaluate prognostic factors of outcome regarding different management strategies including watchful observation, microsurgical treatment, endovascular treatment or any combination thereof.
  • Implement and evaluate patient-specific management protocols integrating all available information.
  • Evaluate the impact of the database and use of tools to improve care, reduce costs, support knowledge discovery and promote new industrial developments.

Study Overview

Status

Recruiting

Detailed Description

Clinical history, imaging data, biological samples and information derived from are the main items to be captured to the SwissNeuroFoundation AneurysmDataBase. No limits are set on the number of healthy volunteers and patient cases for whom data can be entered to the SwissNeuroFoundation AneurysmDataBase.

Participants will be recruited from the following sources:

  • Patients arriving at partner clinical centers either as newly diagnosed (incidental cases) or already known for the disease (prevalent cases)
  • Healthy volunteers answering a call, randomly selected subjects from a known population that consent to participate or non genetically linked family members of patients that consent to participate
  • Family members of patients identified as having a familial history of intracranial aneurysm (IA).

Points of consent:

The specific items on which participants are asked to consent:

  • to having been verbally informed of the aims of the project
  • to having read the information sheet about the project, been able to ask questions about the project, and to having received satisfactory answers and enough time to make the decision.
  • to having been informed that any damage that could be directly caused by the participation to the project is covered by insurance.
  • that hospital care providers working on behalf of the project and representatives of the local authorities and ethics commission may access in a strictly confidential term raw data for quality check.
  • to having been informed that participation can be withdrawn anytime without justification and will result in a medical assessment for own security. There will be no impact on future care resulting from withdrawal.
  • to be free to refuse answering questions without requiring any justification and it will have no impact on future care.
  • to understand that data may be used in a non-identifying form for publication.
  • to understand that data provided may form part of future commercial applications, and will not benefit financially from this.
  • to understand and agree that coded data may be used for further cerebrovascular-related research.
  • that they understand that coded data about them or biological samples may be transferred outside the European Union.

The specific items on which participants are asked to agree or disagree:

  • that they agree to provide access to health records, to provide a link from them to the SwissNeuroFoundation AneurysmDataBase, and to complete a questionnaire on their clinical history.
  • give agreement to provide image data to SwissNeuroFoundation AneurysmDataBase.
  • give agreement to provide blood samples to SwissNeuroFoundation AneurysmDataBase.
  • give agreement to use biological samples resulting from therapeutical intervention.
  • give agreement to use saliva and stool samples to SwissNeuroFoundation AneurysmDataBase.
  • give agreement to be re-contacted by SwissNeuroFoundation AneurysmDataBase for further consent or to request further information.
  • give agreement to inform the General Practitioner about the participation to the project.
  • give agreement to contact the General Practitioner to request information on participant whereabouts or limited relevant medical information, if direct contact was unsuccessful during 3 months.
  • request to be informed by the clinician in charge about observations resulting from the project that may have a significant impact on the participant health.
  • request the General Practitioner of the participant to be informed about observations resulting from the project that may have a significant impact on the participant health.

Separate specific points of consent relative to biological samples and genetics:

  • having read the genetic testing information sheet, been able to ask questions about genetic testing, and understanding why the research is being done and any risks involved
  • give agreement to provide blood samples to SwissNeuroFoundation AneurysmDataBase
  • understanding that genetic data arising from samples may form part of future commercial applications, and that they will not benefit financially from this.
  • understanding that they are free to withdraw at any time and may ask for their sample to be destroyed then, or at any other time.
  • agree that blood samples be stored and used for genetic analysis.
  • agree that blood, aneurysm dome, cerebrospinal fluid (CSF) and microdialysis samples be stored and used for further cerebrovascular-related research.
  • agreement that blood samples may be transferred with coded labels to other Universities in the World.

For the purpose of the AneurysmDataBase:

Clinical Information consists of:

  • Demographic information (Pseudonym, Age, Gender, Size, Weight, work and sport activities, habits: smoking, alcool consumption).
  • Personal medical history (Previous strokes, previous epilepsy, previous medication)
  • Family tree denoting known or likely diagnosed IA or subarachnoid hemorrhage (SAH) events.
  • Signs and symptoms (date of ictus, date of diagnosis, mRankin score, Glasgow Coma Scale (GCS), NIH Stroke Scale (NIHSS),Mini Mental State Exam (MMSE), World Federation of Neurosurgeons Scale WFNS, Cranial nerve deficits)
  • Identified epidemiology factors according to check list.
  • Imaging analysis (Presence of SAH, Fisher grade, size of ventricles, size of basal cisterns, volume of hematoma and location, number of aneurysms, location of aneurysms, size of aneurysms, shape of aneurysm)
  • Treatment and outcome information (treatment method, success)
  • Follow-up and outcome information (Quality of life assessment, MMSE, mRankin, NIHSS, Cranial nerve deficits, aneurysms status: stable, growth, treated, partially treated)

Imaging Data consist of:

  • Pseudonymised DICOM files of:
  • MRI angiography (MRA)
  • Computed Tomography Angiography (CTA)
  • 3D reconstruction of Digital Rotation Angiography (3D-DRA)

Samples consist of:

  • Blood in DNA saving solution
  • Blood in RNA saving solution
  • Blood in EDTA
  • CSF
  • Aneurysm dome
  • Saliva
  • Stool
  • Other biological sample to be specified

Study Type

Observational

Enrollment (Estimated)

20000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Sven Hirsch, Dr
  • Phone Number: +41 58 934 54 44
  • Email: hirc@zhaw.ch

Study Contact Backup

Study Locations

      • Montreal, Canada
        • Recruiting
        • Montreal Neurological Institute and Hospital, McGill University
        • Contact:
          • Guy Rouleau
      • Helsinki, Finland
        • Recruiting
        • Helsinki University Central Hospital
        • Contact:
          • Behman Rezai Jahromi
      • Kuopio, Finland
        • Recruiting
        • Kuopio University Hospital
        • Contact:
          • Antti Lindgren
      • Nantes, France
        • Recruiting
        • ICAN
        • Contact:
          • Romain Bourcier
      • Munich, Germany
        • Recruiting
        • Department of Neurosurgery, Klinikum rechts der Isar, Technical University Munich
        • Contact:
          • Maria Wostrack
        • Sub-Investigator:
          • Isabel Hostettler
      • Pécs, Hungary
        • Completed
        • University of Pécs
      • Rotterdam, Netherlands
        • Completed
        • Erasmus Medical Center
      • Utrecht, Netherlands
        • Recruiting
        • University Medical Center Utrecht
        • Contact:
          • Ynte Ruigrok
      • Krakow, Poland
        • Recruiting
        • Jagiellonian University Medical College
        • Contact:
          • Joanna Pera
      • Barcelona, Spain
        • Completed
        • Barcelona Hospital General de Cataluna
      • Barcelona, Spain
        • Completed
        • Hospital Clinic Barcelona
      • Barcelona, Spain
        • Recruiting
        • IMIM - Hospital del Mar
        • Contact:
          • Jordi Jimenez Corde
      • Geneva, Switzerland, 1211
        • Recruiting
        • Neurochirurgie / Hôpitaux Universitaire de Genève
        • Contact:
        • Contact:
      • Lausanne, Switzerland, 1011
        • Recruiting
        • University Hospital of Lausanne (CHUV), CoLaus Datacenter
        • Contact:
          • Peter Vollenweider, Prof
      • Sankt Gallen, Switzerland
        • Recruiting
        • Department of Neurosurgery, Cantonal Hospital St. Gallen
        • Contact:
          • Isabel Hostettler
      • Zurich, Switzerland, 8008
      • London, United Kingdom
        • Recruiting
        • University College London
        • Contact:
          • David Werring
      • Oxford, United Kingdom
        • Completed
        • Radcliffe Infirmary
      • Sheffield, United Kingdom
        • Completed
        • Royal Hallamshire Hospital
    • California
      • San Francisco, California, United States
        • Recruiting
        • University of California
        • Contact:
          • Nerissa Ko
    • Ohio
      • Cincinnati, Ohio, United States
        • Recruiting
        • University of Cincinnati College of Medicine
        • Contact:
          • Joseph Broderick
        • Sub-Investigator:
          • Daniel Woo
    • Virginia
      • Virginia Beach, Virginia, United States
        • Recruiting
        • University of Virginia
        • Contact:
          • Bradford Worrall

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Prospective consecutive recruitment of cases newly diagnosed intracranial aneurysm in each participating clinical center.

Description

Inclusion Criteria:

  • able to provide consent or, in the event that a patient is incapable of providing consent, that a person is legally authorized to do so on behalf of the patient according to legal and ethical requirements of the country where the clinical centre is located.

Patients:

  • must have an angiographically proven intracranial aneurysm (MRA< CTA< DSA accepted).The determination of SAH requires the presence of a subarachnoid haemorrhage be verified on CT or by lumbar puncture.

MRA: Magnetic Resonance Angiography CTA: Computed Tomography Angiography DSA: Digital Subtracted Angiography

Exclusion Criteria:

  • failure of a candidate to contribute clinical data,
  • refusal to provide informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
IA Patients
Patients with one or more identified intracranial aneurysm, none of which are believed to have ruptured.
IA + SAH Patients
Patients with one or more identified intracranial aneurysm, at least one of which has been radiologically or surgically determined to have ruptured.
Familiy members
Individuals selected on review of a patient's family tree and contacted by said patient, who agree to be approached for recruitment. In affected families each member will be identified as: proband, affected, unaffected, unknown, or not genetically linked.
Healthy Volunteers
Individuals, accompanying or contacted by a patient, or responding to open advertisement, or randomly selected in a defined population who agree to be approached for recruitment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disease model validation
Time Frame: 5 years
Validation and improvement of the holistic disease model
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Life expectancy
Time Frame: 20 years
Age at death
20 years
Disability
Time Frame: 20 years
Disease induced disability on modified Rankin scale and duration of disability
20 years
Cure
Time Frame: 20 years
Absence of new treatments or bleeding after initial treatment
20 years
Adverse events
Time Frame: 20 years
Aneurysm rupture after diagnosis or treatment related severe complications
20 years
Aneurysm growth
Time Frame: 20 years
Observation of the growth of an aneurysm after diagnosis
20 years
Radiological aneurysm exclusion
Time Frame: 20 years
Ability to completely and permanently exclude the lesion with the treatment
20 years
Recurrence
Time Frame: 20 years
Recurrence or repermeabilisation of the aneurysm after treatment
20 years
Neo-aneurysm formation
Time Frame: 20 years
New identification of aneurysm during follow up previously not diagnosed
20 years
Neurological status
Time Frame: 20 years
regular measurement of the NIHSS during follow-up
20 years
Cranial nerves status
Time Frame: 20 years
regular evaluation of cranial nerve function during follow-up
20 years
Occurence of hydrocephalus
Time Frame: 20 years
need for internal CSF drainage system implantation
20 years
Occurence of vasospasm
Time Frame: 20 years
need for aggressive hypertensive treatment or endo-vascular rescue therapy (IA vasodilator injection, balloon angioplasty)
20 years
Quality of life
Time Frame: 20 years
regular measurement of quality of life during follow-up (i.e. EQ-5D)
20 years
Neuropsychological performance
Time Frame: 20 years
regular measurement of neuropsychological performance (i.e. MMSE, MOCA, dedicated evaluation)
20 years
Delayed Cerebral Injury (DCI)
Time Frame: 20 years
Radiological secondary brain injury associated to vasospasm excluding injuries associated with aneurysm intervention
20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Philippe Bijlenga, PD MD PhD, Geneva University
  • Study Chair: Sandrine Morel, PD PhD, Hôpitaux Universitaire de Genève

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2015

Primary Completion (Estimated)

March 1, 2040

Study Completion (Estimated)

March 1, 2040

Study Registration Dates

First Submitted

August 31, 2022

First Submitted That Met QC Criteria

August 31, 2022

First Posted (Actual)

September 2, 2022

Study Record Updates

Last Update Posted (Estimated)

January 16, 2026

Last Update Submitted That Met QC Criteria

January 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified information will be made available upon justifed request and approval by the board of ADB and ethics commissions of institutions that provided data

IPD Sharing Time Frame

The data will be made available to the requesting party within 3 months and for a duration of 5 years with possible extension upon request. IPD data made available to the data user shell be destroyed at the end of the data sharing agreement.

IPD Sharing Access Criteria

Any research on intracranial aneurysms

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intracranial Aneurysm

Subscribe